Key points from article :
Mayo Clinic today announced a strategic collaboration with National Resilience Inc. in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
The focus will be on therapies derived from human sources known as biologics — cells, blood, enzymes, tissues, genes or genetically engineered cells — for use in medicines.
"Mayo is making significant investments in facilities ... create thriving biotherapeutic companies," says Julie Allickson director of Mayo clinics.
The collaboration has these areas of focus:
- Process development expertise to advance Mayo Clinic biotherapeutics.
- Working together to attract biotech companies interested in sponsoring clinical trials at Mayo Clinic for novel regenerative biotherapeutics.
- Providing cell and gene products needed for biomanufacturing early-stage therapeutics.
- Analytical testing and quality control required for manufacturing commercial grade biopharmaceuticals.
